Tissue inhibitor of metalloproteinase type three (TIMP-3)...

Details Tissue inhibitor of metalloproteinase type three (TIMP-3)... Tissue inhibitor of metalloproteinase type three (TIMP-3)...

2006-05-04

2008-10-14

Martinell, James (Department: 1634)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

07435719

ABSTRACT:
The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such inhibitors. In particular, the invention relates to novel mammalian inhibitors of metalloproteinase, which are designated as type three or TIMP-3, to fragments, derivatives, and analogs thereof, and to polynucleotides encoding the same. Novel methods of producing such compositions and novel methods of using such compositions are also provided.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4710473 (1987-12-01), Morris
patent: 5595885 (1997-01-01), Stetler-Stevenson et al.
patent: 6562596 (2003-05-01), Silbiger et al.
patent: 6683155 (2004-01-01), Silbiger et al.
patent: 2003/0143693 (2003-07-01), Silbiger et al.
patent: 0398753 (1990-11-01), None
patent: WO-91/05795 (1991-05-01), None
Apodaca et al., Cancer Res. 50:2322-2329 (1990).
Apte et al., Chemical Abstract 121:197175 (1994).
Apte et al., Genomics 19:86-90 (1994).
Banda et al., Biochem. J. 193:589-605 (1981).
Baron et al., Cell 28:395-404 (1982).
Bauer et al., J. Exp. Med. 148:1378-1387 (1978).
Boone et al., PNAS-USA 87:2800-2804 (1990).
Brannstrom et al., Endocrinology 122:1715-1721 (1988).
Brown et al., American J. of Ophthalmology 72:1139-1142 (1971).
Carlos et al., Immunol. Rev. 114:5-28 (1990).
Carmichael et al., PNAS-USA 83:2407-2411 (1986).
Cawston et al., J. Biochem. 211:313-318 (1983).
Chomczynski and Sacchi, Anal. Biochem. 162:156-159 (1987).
Cocuzzi et al., FEBS Letters 307:375-378 (1992).
Collier et al., Genomics 9:429-434 (1991).
D'Armiento et al., Cell 71:955-961 (1992).
DeClerck et al., Cancer Research 46:3580-3586 (1986).
DeClerck et al., J. Biol. Chem. 266:3893-3899 (1991).
Docherty et al., Nature 318:66-69 (1985).
Dreesman et al., Nature 295:158-160 (1982).
Edwards et al., Nucl. Acid. Res. 14:8863-8878 (1986).
Evanson et al., J. Clin. Invest. 47:2639-2651 (1968).
Freudenstein et al., Biochem. Biophys. Res. Comm. 171:250-256 (1990).
Friedman et al., Nucl. Acids Res. 16:8718 (1988).
Gewert et al., EMBO 6:651-657 (1987).
Glorieux et al., Cancer 58:2136-2139 (1986).
Goldberg, J. Biol. Chem. 261:6600-6605 (1986).
Graeve et al., Cancer 62:2125-2127 (1988).
Grantham et al., Nucl. Acid. Res. 9:43-74 (1981).
Gribskov et al., Nucl. Acids Res. 14:6745-6763 (1986).
Herron et al., J. Biol. Chem. 261:2814-2818 (1986).
Hewick et al., J. Biol. Chem. 256:7990-7997 (1981).
Hibbs et al., J. Biol. Chem. 260:2493-2500 (1985).
Hicks et al., Int. J. Cancer 33:835-844 (1984).
Horowitz et al., J. Biol. Chem. 264:7092-7095 (1989).
Huse et al., Science 246:1275-1281 (1989).
Johnson et al., Mol. Cell. Biol. 7:2821-2829 (1987).
Jones et al., FEBS Letters 352:171-174 (1994).
Kaiser et al., Science 223:249-255 (1984).
Khokha et al., Science 243:947-950 (1989).
Kishnani et al., FASEB J. 7, abstract 2148 (1993).
Kishnani et al., Matrix Biol. 14:479-488 (1995).
Kohler and Milstein, Eur. J. Immunol. 6:511-519 (1976).
Leco et al., J. Biol. Chem. 269:9352-9360 (1994).
Lerner et al., Cell 23:309-310 (1981).
Lerner et al., PNAS-USA 78:3403-3407 (1981).
Lerner et al., Scientific Am., 248:66-74 (1983).
Liotta et al., Biochem. Biophys. Res. Commun. 98:184-198 (1981).
Liotta et al., Nature 284:67-68 (1980).
Liotta et al., PNAS-USA 76:2268-2272 (1979).
Macartney et al., Eur. J. Biochem. 130:79-83 (1983).
Madshus et al., J. Biol. Chem. 266:17446-17453 (1991).
Matrisian, Trends in Genetics 6:121-125 (1990).
Murphy et al., Biochem. 195:167-170 (1981).
Murphy et al., Biochem. J. 203:209-221 (1982).
Murray et al., J.Biol. Chem. 261:4154-4159 (1986).
Nigg et al., PNAS-USA 79:5322-5326 (1982).
Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,” Dec. 7, 1995, National Institutes of Health, Bethesda, MD.
Palmiter et al., Science 222:809-814 (1983).
Pavloff et al., J. Biol. Chem. 267:17321-17326 (1992).
Pisko et al., J. Immunol. 136:2141-2150 (1986).
Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pp. 697-773.
Ross et al., Nature 294:654-656 (1981).
Salo et al., J. Biol. Chem. 258:3058-3063 (1983).
Schepens et al., Mol. Biol. Rep. 16:241-248 (1992).
Schultz et al., Cancer Research 48:5539-5545 (1988).
Shimizu et al., Gene 114:291-292 (1992).
Silbiger et al., Gene 141:293-297 (1994).
Slansky et al., Annals of Ophthalmology 2:488-491 (1970).
Staskus et al., J. Biol. Chem. 266:449-454 (1991).
Stetler-Stevenson et al., J. Biol. Chem. 264:17374-17378 (1989).
Stetler-Stevenson et al., J. Biol. Chem. 265:13933-13938 (1990).
Stricklin et al., J. Biol. Chem. 258:12252-12258 (1983).
Tartof and Hobbs, Bethesda Res. Lab. Focus 9:12 (1987).
Thorgeirsson et al., J. Natl. Canc. Inst. 69:1049-1054 (1982).
Tolley et al., J. Mol. Biol. 229:1163-1164 (1993).
Tramontano et al., Nucleic Acid Res. 12:5049-5059 (1984).
Uitto, V.-J., In Proteinases in Inflammation and Tumor Invasion, H. Tschesche, Ed., Walter de Gruyter & Co., Berlin, NY, 211-223 (1988).
Uria et al., Cancer Res. 54:2091-2094 (1994).
Van Ranst et al., Cytokine 3:231-239 (1991).
Verma, Scientific American 263:68-84 (1990).
Vincenti et al., Arthritis and Rheumatism 37:1115-1126 (1994).
Wallace et al., Methods Enzymol. 152:432-442 (1987).
Walter et al., PNAS-USA 77:5197-5200 (1980).
Walter et al., PNAS-USA 78:4882-4886 (1981).
Weiland et al., Blut 44:173-175 (1982).
Werb et al., J. Exp. Med. 142:346-360 (1975).
Willenbrock et al., Biochemistry 32:4330-4337 (1993).
Woolley et al., Arthritis and Rheumatism 20:1231-1239 (1977).
Yang et al., PNAS-USA 89:10676-10680 (1992).
Zucker et al., Int. J. Cancer 52:366-371 (1992).
Office Action in U.S. Appl. No. 08/134,231, mailed on Jan. 10, 1995.
Response filed in U.S. Appl. No. 08/134,231, on Apr. 14, 1995.
Office Action in U.S. Appl. No. 08/134,231, mailed on Jul. 11, 1995.
Response filed in U.S. Appl. No. 08/134,231, on Dec. 11, 1995.
Interview Summary in U.S. Appl. No. 08/134,231, mailed on Feb. 5, 1996.
Response filed in U.S. Appl. No. 08/134,231, on Feb. 20, 1996.
Office Action in U.S. Appl. No. 08/134,231, mailed on Dec. 14, 2001.
Response filed in U.S. Appl. No. 08/134,231, on May 13, 2002.
Office Action in U.S. Appl. No. 08/134,231, mailed on Jul. 29, 2002.
Response filed in U.S. Appl. No. 08/134,231, on Sep. 6, 2002.
Office Action in U.S. Appl. No. 08/728,160, mailed on Feb. 28, 1997.
Response filed in U.S. Appl. No. 08/728,160, on Jun. 30, 1997.
Office Action in U.S. Appl. No. 08/728,160, mailed on Oct. 15, 1997.
Response filed in U.S. Appl. No. 08/728,160, on Feb. 17, 1998.
Interview Summary in U.S. Appl. No. 08/728,160, mailed on Mar. 13, 1998.
Office Action in U.S. Appl. No. 08/728,160, on Jun. 12, 2002.
Response filed in U.S. Appl. No. 08/728,160, on Oct. 10, 2002.
Office Action in U.S. Appl. No. 08/728,160, mailed on Dec. 4, 2002.
Response filed in U.S. Appl. No. 08/728,160, on Feb. 13, 2003.
Advisory Action in U.S. Appl. No. 08/728,160, mailed on Mar. 6, 2003.
Response filed in U.S. Appl. No. 08/728,160, on Apr. 2, 2003.
Office Action in U.S. Appl. No. 10/348,167, mailed on May 17, 2005.
Response filed in U.S. Appl. No. 10/348,167, on Nov. 3, 2005.
European Search Report for European Patent Application No. 94115578, dated Jan. 17, 1995.
European Patent Office Examination Report for European Patent Application No. 94115578, dated Jun. 25, 1998.
European Patent Office Examination Report for European Patent Application No. 94115578, dated Jan. 29, 1999.
European Patent Office Examination Report for European Patent Application No. 94115578, dated Nov. 29, 1999.
European Patent Office Examination Report for European Patent Application No. 94115578, dated Oct. 5, 2000.
European Patent Office Examination Report for European Patent Application No. 94115578, dated Apr. 5, 2001.
European Patent Office Examination Report for European Patent Application No. 94115578, dated Sep. 28, 2001.
European Search Report for European Patent Application No. 03005363, dated Aug. 6, 2003.
European Patent Office Examination Report for European Patent Application No. 03005363, dated Sep. 8, 2004.
European Patent Office Examination Report for

Affiliated with

Also associated with

Rating

Tissue inhibitor of metalloproteinase type three (TIMP-3)... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tissue inhibitor of metalloproteinase type three (TIMP-3)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue inhibitor of metalloproteinase type three (TIMP-3)... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3994652